Butterfly Network today announced preliminary, unaudited revenue for the fourth quarter ended December 31, 2025, grew by at least 17% year over year. This marks the fourth consecutive quarter of double-digit revenue expansion for the company’s handheld ultrasound business. Management indicated that growth was driven by increased device placements across North America and accelerated adoption in emerging markets, where new distributor agreements added over 200 trained sites during the quarter. The company expects to report audited fourth quarter and full year results in late February and to provide full year 2026 guidance at that time.

On January 7, 2026, Executive Vice President John Doherty sold 60,182 shares of company stock in a disclosed transaction valued at approximately $240,000. Following the sale, Mr. Doherty’s remaining ownership stands at 1,234,688 shares, representing a 4.65% reduction in his position. The move forms part of a broader pattern of insider sales this week, including those by the CTO and a board director, which may intensify short-term trading pressure despite continued institutional support.

Butterfly Network is covered by five research analysts, with three Buy ratings, one Hold and one Sell, yielding an average recommendation of Hold. The consensus price target sits near $3.67, reflecting mixed expectations for near-term earnings improvement. Institutional investors hold approximately 37.85% of the company’s shares, led by Geode and Acadian, both of which increased their stakes in late 2025. Recent inflows by asset managers signal confidence in Butterfly’s long-term growth trajectory, even as the company remains loss-making and works to expand its software and chip-licensing offerings.

Chief Executive Officer Joseph DeVivo will outline the company’s 2026 roadmap at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. Management plans to detail upcoming product enhancements, including the introduction of a beam-steering API to unlock advanced 3D imaging capabilities for third-party developers. Combined with expanding co-development and chip licensing partnerships, Butterfly expects 2026 to be a pivotal inflection year for margin improvement and accelerated commercial scaling.